Aperture Therapeutics
Aperture Therapeutics is dedicated to curing neurodegenerative diseases and delaying brain aging by leveraging human genetic resilience. They identify gene variants that drive disease resilience, build cell libraries for drug testing, and develop drugs that mimic protective gene variants. Their mission is to transform the strengths of human genetics into protective medicines, with out-licensing and co-development partnerships in various neurological conditions. They are supported by a diverse group of investors and are based in San Carlos, CA.
Industries
Nr. of Employees
small (1-50)
Aperture Therapeutics
Products
Preclinical therapeutic programs inspired by protective human variants
Preclinical-stage drug development programs that use protective human genetic variants as the basis for RNA/oligonucleotide therapeutic candidates targeting neurodegenerative and related indications.
Preclinical therapeutic programs inspired by protective human variants
Preclinical-stage drug development programs that use protective human genetic variants as the basis for RNA/oligonucleotide therapeutic candidates targeting neurodegenerative and related indications.
Services
Partnering and licensing for early-stage programs
Collaborative and licensing engagements enabling external partners to access RNA/oligonucleotide discovery capabilities and preclinical development services for neurodegenerative and neuroimmune indications.
Partnering and licensing for early-stage programs
Collaborative and licensing engagements enabling external partners to access RNA/oligonucleotide discovery capabilities and preclinical development services for neurodegenerative and neuroimmune indications.
Expertise Areas
- Genetic variant discovery and interpretation
- RNA and oligonucleotide drug discovery
- Preclinical in vivo pharmacology
- High-throughput assay development
Key Technologies
- RNA/oligonucleotide therapeutics
- Cell library generation
- High-throughput screening and assay automation
- qPCR / qRT-PCR